Antioxidant Effect of Thioredoxin and Vitamin D3 in Peritoneal Dialysis Patients

Table 1

Distribution of disease-related features.

		min-max
Peritoneal dialysis duration (year)		0,16-13,11
CAPD duration		2-156
Previous HD duration() (month)		1-144
Daily dwell volume		6000-13000
Daily dwell changing number		1-5
Utrafiltration (ml)		0,20-4,0
Residual urine (ml)		0-3000
			%
Previous hemodialysis	Present	8	11,6
	Absent	61	88,4
Peritoneal dialysis type	CAPD	62	89,9
	APD	7	10,1
Etiology	HT	32	46,4
	DM	19	27,5
	Polycystic kidney disease	8	11,6
	GMN	8	11,6
	Other	2	2,9
Medical treatment	Dextroz sol.	69	100
	Icodextran sol.	36	52,2
	Amino acid sol.	14	20,3
	Erythropoietin	33	47,8
	Blood transfusion	1	1,4
	Antilipidemic	19	27,5
	OAD	1	1,4
	Insulin	18	26,1
	Iron replacement	16	23,2
	Amino acid replacement	28	40,6
	Phosphorus binding	39	56,5
	Vitamin D3	40	58,0
	Other drugs	2	2,8

CAPD: Continuous ambulatory peritoneal dialysis; HD: Hemodialysis; APD: Automated peritoneal dialysis; HT: Hypertension; DM: Diabetes mellitus, GMN: Glomerulonephritis; OAD: Oral antidiabetics.